You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swiss-Finnish Aurealis Therapeutics has entered into an exclusive license and collaboration agreement with Xbiome for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Already a subscriber Login You have read all your free articles, to…
The companies have signed a collaboration and distribution agreement that gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe. “Partnering with Thermo Fisher, the leading innovator in theAlready a subscriber Login You have read all your free articles,…
The company has announced an increased focus on its strategy around its core AI capabilities allowing fast and de-risked development of its pipeline. Recently, Evaxion announced that the company has used its AI technology to discover a new treatment opportunity that may broaden cancer immunotheraAlready a subscriber Login You have…
The company has announced that it is initiating the development of a vaccine directed against ROR. Kancera's strategy is, according to the Karolinska Institutet Science Park company, to use its future small-molecule ROR inhibitors as a first line treatment for the disease and thereafter follow Already a subscriber Login You have read…
